Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology 2024-11-22 10:15
United Imaging Announces the First of Several New U.S. Product Launches For RSNA 2024-11-22 03:00
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development 2024-11-21 23:46
I-Mab to Participate at the Piper Sandler Healthcare Conference 2024-11-21 20:00
111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024 2024-11-21 18:00
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation 2024-11-21 15:09
DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation 2024-11-21 13:01
United Imaging Installs Another Flagship uMR OMEGA®, in New Mexico 2024-11-21 09:09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP 2024-11-21 01:01
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity 2024-11-20 22:00
CABIO Deepens Commitment to Global Markets, Aiming to Serve International Clients and Pursue Long-Term International Partnerships 2024-11-20 21:00
Head：China makes collaborative efforts in healing people with mental disorders with AI 2024-11-20 15:13
Forging New Paths: Alfasigma Group and Fangzhou Inc. Chart a Course for Internet Healthcare 2024-11-20 10:38
Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B 2024-11-20 07:20
Datasea Pre-Announces Full-Year Fiscal 2025 Revenue of $90 Million, Representing a Year-Over-Year Increase of 275%, with Expected Significant Gross Profit Improvement 2024-11-19 22:45
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS 2024-11-19 21:26
Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity 2024-11-19 21:00
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study 2024-11-19 20:30
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development 2024-11-19 16:00
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects 2024-11-19 14:08
1 4 5 6 7 8 436